Efficacy, safety and pharmacokinetics of 1,2,4-trioxolane OZ78 against an experimental infection with Fasciola hepatica in sheep

Jennifer Keiser, Carla Kirchhofer, Manuel Haschke, Jörg Huwyler, Yuxiang Dong, Jonathan L. Vennerstrom, Kathleen Vanhoff, Ronald Kaminsky, Nick Malikides

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The synthetic peroxide OZ78 is an effective flukicide in the rodent model, but the potential of OZ78 in target animals has not been studied to date. In the present study, OZ78 was administered at 50mg/kg orally and subcutaneously to sheep harbouring an experimental Fasciola hepatica infection and the efficacy, tolerability and pharmacokinetic profiles were monitored. OZ78 given orally or subcutaneously revealed no effect neither on faecal egg counts nor on worm burdens. Apart from significant subcutaneous swelling at the injection sites of most of the treated animals, no other treatment related adverse events occurred. OZ78 had no significant effect on any haematological, coagulation or clinical chemistry variables tested. Following oral administration, a mean Cmax of 45.8±13μg/ml was reached after 1h. An estimated elimination half-life of 1.0h and a mean AUC of 116.2±47μgmin/ml was calculated for the oral administration. Following subcutaneous treatment with OZ78 Cmax and tmax were 13.7±6.1μg/ml and 0.9±0.4h, respectively. The α and β half-lives were 4.5±4.3h and 56.5±36h, respectively and the mean AUC was 219.1±74μgmin/ml. Further studies are needed to determine whether the excellent activity observed with OZ78 in the rat model can be translated into efficacy in larger mammals.

Original languageEnglish (US)
Pages (from-to)228-235
Number of pages8
JournalVeterinary Parasitology
Volume173
Issue number3-4
DOIs
StatePublished - Oct 29 2010

Fingerprint

Fasciola hepatica
oral administration
pharmacokinetics
half life
Area Under Curve
Oral Administration
Sheep
Pharmacokinetics
Safety
sheep
Clinical Chemistry
injection site
fecal egg count
Peroxides
Infection
coagulation
peroxides
infection
Ovum
Half-Life

Keywords

  • 1,2,4-Trioxolane
  • Egg count
  • Experimental infection
  • Fasciola hepatica
  • Fascioliasis
  • LC-MS
  • Lamb
  • OZ78
  • Ozonide
  • Pharmacokinetics
  • Safety
  • Sheep
  • Worm burden

ASJC Scopus subject areas

  • Parasitology
  • veterinary(all)

Cite this

Efficacy, safety and pharmacokinetics of 1,2,4-trioxolane OZ78 against an experimental infection with Fasciola hepatica in sheep. / Keiser, Jennifer; Kirchhofer, Carla; Haschke, Manuel; Huwyler, Jörg; Dong, Yuxiang; Vennerstrom, Jonathan L.; Vanhoff, Kathleen; Kaminsky, Ronald; Malikides, Nick.

In: Veterinary Parasitology, Vol. 173, No. 3-4, 29.10.2010, p. 228-235.

Research output: Contribution to journalArticle

Keiser, Jennifer ; Kirchhofer, Carla ; Haschke, Manuel ; Huwyler, Jörg ; Dong, Yuxiang ; Vennerstrom, Jonathan L. ; Vanhoff, Kathleen ; Kaminsky, Ronald ; Malikides, Nick. / Efficacy, safety and pharmacokinetics of 1,2,4-trioxolane OZ78 against an experimental infection with Fasciola hepatica in sheep. In: Veterinary Parasitology. 2010 ; Vol. 173, No. 3-4. pp. 228-235.
@article{8fe4a86c42eb4cbc8efd7a5465524166,
title = "Efficacy, safety and pharmacokinetics of 1,2,4-trioxolane OZ78 against an experimental infection with Fasciola hepatica in sheep",
abstract = "The synthetic peroxide OZ78 is an effective flukicide in the rodent model, but the potential of OZ78 in target animals has not been studied to date. In the present study, OZ78 was administered at 50mg/kg orally and subcutaneously to sheep harbouring an experimental Fasciola hepatica infection and the efficacy, tolerability and pharmacokinetic profiles were monitored. OZ78 given orally or subcutaneously revealed no effect neither on faecal egg counts nor on worm burdens. Apart from significant subcutaneous swelling at the injection sites of most of the treated animals, no other treatment related adverse events occurred. OZ78 had no significant effect on any haematological, coagulation or clinical chemistry variables tested. Following oral administration, a mean Cmax of 45.8±13μg/ml was reached after 1h. An estimated elimination half-life of 1.0h and a mean AUC of 116.2±47μgmin/ml was calculated for the oral administration. Following subcutaneous treatment with OZ78 Cmax and tmax were 13.7±6.1μg/ml and 0.9±0.4h, respectively. The α and β half-lives were 4.5±4.3h and 56.5±36h, respectively and the mean AUC was 219.1±74μgmin/ml. Further studies are needed to determine whether the excellent activity observed with OZ78 in the rat model can be translated into efficacy in larger mammals.",
keywords = "1,2,4-Trioxolane, Egg count, Experimental infection, Fasciola hepatica, Fascioliasis, LC-MS, Lamb, OZ78, Ozonide, Pharmacokinetics, Safety, Sheep, Worm burden",
author = "Jennifer Keiser and Carla Kirchhofer and Manuel Haschke and J{\"o}rg Huwyler and Yuxiang Dong and Vennerstrom, {Jonathan L.} and Kathleen Vanhoff and Ronald Kaminsky and Nick Malikides",
year = "2010",
month = "10",
day = "29",
doi = "10.1016/j.vetpar.2010.06.031",
language = "English (US)",
volume = "173",
pages = "228--235",
journal = "Veterinary Parasitology",
issn = "0304-4017",
publisher = "Elsevier",
number = "3-4",

}

TY - JOUR

T1 - Efficacy, safety and pharmacokinetics of 1,2,4-trioxolane OZ78 against an experimental infection with Fasciola hepatica in sheep

AU - Keiser, Jennifer

AU - Kirchhofer, Carla

AU - Haschke, Manuel

AU - Huwyler, Jörg

AU - Dong, Yuxiang

AU - Vennerstrom, Jonathan L.

AU - Vanhoff, Kathleen

AU - Kaminsky, Ronald

AU - Malikides, Nick

PY - 2010/10/29

Y1 - 2010/10/29

N2 - The synthetic peroxide OZ78 is an effective flukicide in the rodent model, but the potential of OZ78 in target animals has not been studied to date. In the present study, OZ78 was administered at 50mg/kg orally and subcutaneously to sheep harbouring an experimental Fasciola hepatica infection and the efficacy, tolerability and pharmacokinetic profiles were monitored. OZ78 given orally or subcutaneously revealed no effect neither on faecal egg counts nor on worm burdens. Apart from significant subcutaneous swelling at the injection sites of most of the treated animals, no other treatment related adverse events occurred. OZ78 had no significant effect on any haematological, coagulation or clinical chemistry variables tested. Following oral administration, a mean Cmax of 45.8±13μg/ml was reached after 1h. An estimated elimination half-life of 1.0h and a mean AUC of 116.2±47μgmin/ml was calculated for the oral administration. Following subcutaneous treatment with OZ78 Cmax and tmax were 13.7±6.1μg/ml and 0.9±0.4h, respectively. The α and β half-lives were 4.5±4.3h and 56.5±36h, respectively and the mean AUC was 219.1±74μgmin/ml. Further studies are needed to determine whether the excellent activity observed with OZ78 in the rat model can be translated into efficacy in larger mammals.

AB - The synthetic peroxide OZ78 is an effective flukicide in the rodent model, but the potential of OZ78 in target animals has not been studied to date. In the present study, OZ78 was administered at 50mg/kg orally and subcutaneously to sheep harbouring an experimental Fasciola hepatica infection and the efficacy, tolerability and pharmacokinetic profiles were monitored. OZ78 given orally or subcutaneously revealed no effect neither on faecal egg counts nor on worm burdens. Apart from significant subcutaneous swelling at the injection sites of most of the treated animals, no other treatment related adverse events occurred. OZ78 had no significant effect on any haematological, coagulation or clinical chemistry variables tested. Following oral administration, a mean Cmax of 45.8±13μg/ml was reached after 1h. An estimated elimination half-life of 1.0h and a mean AUC of 116.2±47μgmin/ml was calculated for the oral administration. Following subcutaneous treatment with OZ78 Cmax and tmax were 13.7±6.1μg/ml and 0.9±0.4h, respectively. The α and β half-lives were 4.5±4.3h and 56.5±36h, respectively and the mean AUC was 219.1±74μgmin/ml. Further studies are needed to determine whether the excellent activity observed with OZ78 in the rat model can be translated into efficacy in larger mammals.

KW - 1,2,4-Trioxolane

KW - Egg count

KW - Experimental infection

KW - Fasciola hepatica

KW - Fascioliasis

KW - LC-MS

KW - Lamb

KW - OZ78

KW - Ozonide

KW - Pharmacokinetics

KW - Safety

KW - Sheep

KW - Worm burden

UR - http://www.scopus.com/inward/record.url?scp=77956230893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956230893&partnerID=8YFLogxK

U2 - 10.1016/j.vetpar.2010.06.031

DO - 10.1016/j.vetpar.2010.06.031

M3 - Article

C2 - 20674178

AN - SCOPUS:77956230893

VL - 173

SP - 228

EP - 235

JO - Veterinary Parasitology

JF - Veterinary Parasitology

SN - 0304-4017

IS - 3-4

ER -